Our Next Pathology Oncology Digital Series:

March 19, 2026

Our Next Pathology
Oncology Digital Series:

March 19, 2026

REGISTER FOR THE NEXT CAMP PODS CLICK HERE

WELCOME

CAMP PODS is a webinar series, consisting of nine one-hour sessions that will take place from January to November 2026 for an hour once a month.

The goal of this series is to build a strong Oncology Laboratory Medicine community, where best practices and common challenges can be discussed.  Insights gained will be key to implement across Canada and will help streamline laboratory workflows and practice for laboratory medicine, the end result of which will be improvements in the patient journey.

Overall Learning Objectives:

By the end of the webinar series, an audience member will:

  1. Establish a strong Oncology Education Network
  2. Compare ideas, thoughts and common challenges
  3. Identify gaps and find team solutions for improving patient care
  4. Integrate pathology and oncology practices

NEXT CAMP PODS SESSION

Thursday, March 19, 2026
9:00am – 9:45 am PT Beyond Morphology: Harnessing Molecular and Immunohistochemical Biomarkers in Cytologic Specimens Deepu Alex, M.D., Ph.D.

Consultant Pathologist, BC Cancer Agency
Clinical Associate Professor, Department of Pathology and Laboratory Medicine, 
The University of British Columbia (UBC)
Vancouver, BC
9:45am  – 10:00am PT Questions & Answers
Learning objectives:
By the end of this presentation, participants will be able to:

  1. Explain the expanding role of cytopathology specimens in molecular diagnostics, including the pre-analytic factors that influence specimen selection
  2. Distinguish between clinical sensitivity and analytic sensitivity, and describe how these concepts apply to the interpretation of test results from cytologic specimens
  3. Identify the types of genetic alterations detectable by next-generation sequencing and compare the principles and performance characteristics of key molecular assay platforms
  4. Apply knowledge of immunohistochemical and molecular biomarkers to guide testing in cytology specimens for targeted therapy
  5. Recognize the utility of multimodal approaches that allow cytology and surgical pathology specimens to be used in conjunction for maximal tumor profiling

OUR LAST CAMP PODS SESSION

Thursday, February 26, 2026
9:00am – 9:45 am PT Emerging Immunohistochemical Biomarkers in Ovarian Cancer Basile Tessier-Cloutier, MD

Consultant Gynecologic Pathologist, McGill University Health Centre (MUHC)
Principal Investigator, Research Institute (RI-MUHC)
Montreal, QC
9:45am  – 10:00am PT Questions & Answers
Learning objectives:
By the end of this presentation, participants will be able to:

  1. Present and discuss emerging immunohistochemical biomarkers in ovarian cancer and their impact on clinical decision-making.
  2. Review current and potential practices of immunohistochemistry testing in ovarian cancer.
  3. Discuss how pathology findings integrate with molecular and immunohistochemical results to guide personalized treatment strategies